CHF255.60
0.47% yesterday
SIX Swiss Exchange, Apr 17, 05:31 pm CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Target price 2025 - Analyst rating & recommendation

Roche Classifications & Recommendation:

Buy
48%
Hold
36%
Sell
16%

Roche Price Target

Target Price CHF310.90
Price CHF255.60
Potential 21.64%
Number of Estimates 20
20 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF310.90. This is 21.64% higher than the current stock price. The highest price target is CHF448.00 75.27% , the lowest is CHF230.00 10.02% .
A rating was issued by 25 analysts: 12 Analysts recommend Roche to buy, 9 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 21.64% . Most analysts recommend the Roche stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion CHF 60.50 64.35
3.03% 6.38%
EBITDA Margin 35.81% 39.71%
6.07% 10.89%
Net Margin 13.66% 23.24%
29.92% 70.12%

20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF64.4b . This is 6.38% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF67.0b 10.74% , the lowest is CHF62.7b 3.60% .

This results in the following potential growth metrics:

Revenue Estimates

2024 CHF60.5b 3.03%
2025 CHF64.4b 6.38%
2026 CHF67.3b 4.55%
2027 CHF69.8b 3.74%
2028 CHF72.5b 3.94%
2029 CHF75.1b 3.53%

18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.6b . This is 21.48% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.1b 29.03% , the lowest is CHF21.9b 4.08% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 CHF21.7b 9.28%
2025 CHF25.6b 17.97%
2026 CHF26.9b 5.16%
2027 CHF27.8b 3.30%
2028 CHF29.6b 6.77%
2029 CHF29.4b 0.67%

EBITDA Margin

2024 35.81% 6.07%
2025 39.71% 10.89%
2026 39.94% 0.58%
2027 39.77% 0.43%
2028 40.86% 2.74%
2029 39.20% 4.06%

14 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.0b . This is 80.94% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.0b 105.34% , the lowest is CHF10.4b 25.99% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 CHF8.3b 27.80%
2025 CHF15.0b 80.94%
2026 CHF16.1b 7.51%
2027 CHF16.9b 5.17%
2028 CHF17.0b 0.79%
2029 CHF18.9b 10.79%

Net Margin

2024 13.66% 29.92%
2025 23.24% 70.12%
2026 23.89% 2.80%
2027 24.22% 1.38%
2028 23.49% 3.01%
2029 25.14% 7.02%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share CHF 10.39 18.80
27.80% 80.94%
P/E 13.60
EV/Sales 3.52

14 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF18.80 . This is 80.94% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF21.33 105.29% , the lowest is CHF13.09 25.99% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 CHF10.39 27.80%
2025 CHF18.80 80.94%
2026 CHF20.21 7.50%
2027 CHF21.26 5.20%
2028 CHF21.42 0.75%
2029 CHF23.74 10.83%

P/E ratio

Current 24.60 57.49%
2025 13.60 44.72%
2026 12.65 6.99%
2027 12.03 4.90%
2028 11.93 0.83%
2029 10.77 9.72%

Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.52 and an P/S ratio of 3.16 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.75 8.07%
2025 3.52 6.05%
2026 3.37 4.35%
2027 3.25 3.61%
2028 3.13 3.79%
2029 3.02 3.41%

P/S ratio

Current 3.36 10.01%
2025 3.16 6.00%
2026 3.02 4.35%
2027 2.91 3.61%
2028 2.80 3.79%
2029 2.71 3.41%

Current Roche Upgrades & Downgrades

Analyst Rating Action Date
BERENBERG
Hold
Hold
Unchanged Apr 07 2025
TD COWEN
Hold
Hold
Unchanged Apr 06 2025
HSBC
Buy
Buy
Unchanged Mar 23 2025
REDBURN ATLANTIC
Buy
Buy
Unchanged Mar 21 2025
JEFFERIES
Hold
Hold
Unchanged Mar 11 2025
STIFEL EUROPE
Hold
Hold
Unchanged Mar 02 2025
DZ BANK
Buy
Buy
Unchanged Feb 02 2025
Analyst Rating Date
Unchanged
BERENBERG:
Hold
Hold
Apr 07 2025
Unchanged
TD COWEN:
Hold
Hold
Apr 06 2025
Unchanged
HSBC:
Buy
Buy
Mar 23 2025
Unchanged
REDBURN ATLANTIC:
Buy
Buy
Mar 21 2025
Unchanged
JEFFERIES:
Hold
Hold
Mar 11 2025
Unchanged
STIFEL EUROPE:
Hold
Hold
Mar 02 2025
Unchanged
DZ BANK:
Buy
Buy
Feb 02 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today